Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 105

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 105
---
 market and in the German market, which are not related to the Company. In accordance with the separation agreement signed
between the parties on that date, the loan that the Company provided to an IMC subsidiary within the framework of the aforementioned

MOU, amounting to USD $300 thousand,
will be repaid to the Company plus annual interest at a rate of 9% for the outstanding period, in 3 equal installments, the last of which
was to be transferred to the Company no later than July 31, 2024 and to which the interest accrued during the period would be added. The
balance of the loan was recorded in accounts receivable. As of June 30, 2024, the balance of the loan was USD $188 thousand and financing
income was recorded in respect thereof amounting to USD $8 thousand. As of the date of these financial statements, the Company has collected
all payments in accordance with the separation agreement, and as of December 31, 2024, there is no balance outstanding.

<div align='center'>F-31</div>

| H. | Agreement with Pluri Inc. |

On July 17, 2024, the Company entered
into a collaboration agreement with Pluri Inc. (Nasdaq: PLUR) (hereinafter, “Pluri”) for the clinical manufacturing (outsourced)
of the Company’s products (hereinafter, the “Pluri Agreement”) at Pluri’s manufacturing facility in accordance
with the Company’s strategic plan.

The signing of the Pluri Agreement to
manufacture the Company’s products constitutes a milestone in the development of the ASTRORX product, as part of
the Company’s preparation for a multi-site Phase IIA clinical trial (Phase A2), as well as in the development of the ISLETRX product
in support of the Pre-IND submission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment
within the framework of the aforementioned collaboration and as preparation for the submission of an IND application in the future. In
accordance with the agreement, the Company will grant Pluri the right to use the knowledge developed by the Company for the benefit of
Pluri’s production of the Company’s products, with the first phase lasting up to 12 months, in consideration of approximately
USD $70,000 to be paid in cash or through issuance of Company securities, as to be agreed upon by the parties.

The agreement stipulates a number